ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Fosfomycin susceptibility and molecular detection of fosA-mediated resistance among gram-negative uropathogens from a tertiary care hospital in Lucknow, India.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) remain a major clinical challenge due to the increasing prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative uropathogens. Fosfomycin has regained importance as a therapeutic option against resistant urinary pathogens because of its unique mechanism of action and limited cross-resistance with other antimicrobial agents. However, the emergence of resistance mechanisms, particularly plasmid-mediated fosA genes, threatens its long-term clinical utility. This study employed a combined phenotypic-genotypic approach to evaluate fosfomycin resistance through minimum inhibitory concentration (MIC) determination and molecular detection of the fosA gene among Gram-negative uropathogens isolated from patients with UTIs. This prospective observational study was conducted from June 2023 to December 2024 at the Integral Institute of Medical Sciences and Research (IIMSR), Lucknow. A total of 2,550 urine samples were analyzed. Significant Gram-negative isolates were subjected to antimicrobial susceptibility testing (AST), extended-spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacterales (CRE) screening, and fosfomycin susceptibility testing using the Kirby-Bauer disc diffusion and agar dilution methods for MIC determination according to Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Fosfomycin-resistant isolates were further evaluated for the presence of the fosA gene using conventional polymerase chain reaction (PCR). Agreement between disc diffusion and MIC methods was assessed to determine diagnostic reliability. Of the 2,550 urine samples processed, 651 showed significant bacterial growth, yielding 371 Gram-negative isolates. Escherichia coli (79.5%) was the predominant pathogen. Fosfomycin demonstrated high overall susceptibility, with 91.6% susceptibility by disc diffusion and 94.8% by agar dilution. The high categorical agreement (96%) between both methods supports the utility of disc diffusion as a reliable screening method for fosfomycin susceptibility testing. Fosfomycin retained excellent activity against resistant phenotypes, including ESBL-producing (93%), MDR (94%), and CRE (89.6%) isolates. Fosfomycin MIC values ranged from 0.25 to 256 µg/mL, with most isolates showing MIC values within the susceptible range. The fosA gene was detected in 78.9% (15/19) of phenotypically fosfomycin-resistant isolates tested, predominantly among E. coli (84.6%) and Klebsiella pneumoniae (100%) isolates. Fosfomycin demonstrated preserved in vitro activity against Gram-negative uropathogens, including ESBL-producing, MDR, and CRE isolates. The detection of fosA among resistant isolates highlights the emergence of transferable fosfomycin resistance mechanisms and emphasizes the importance of continuous molecular surveillance combined with phenotypic susceptibility testing to support antimicrobial stewardship.
Indexed as
Identifiers
42467203What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.